Centro de Imagem Diagnósticos S.A Net Assets

Latest as of December 2025: R$-252.23 Million BRL ≈ $-49.49 Million USD

Centro de Imagem Diagnósticos S.A net assets. Based on the latest financial reports, Centro de Imagem Diagnósticos S.A (AALR3) has net assets worth R$-252.23 Million BRL (≈ $-49.49 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (R$1.78 Billion ≈ $348.75 Million USD) and total liabilities (R$2.03 Billion ≈ $398.24 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Centro de Imagem Diagnósticos S.A annual equity growth to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric Value
Current Net Assets R$-252.23 Million
% of Total Assets -14.19%
Annual Growth Rate N/A
5-Year Change -120.86%
10-Year Change -120.81%
Growth Volatility 162.78

Net Assets of Centro de Imagem Diagnósticos S.A (2010–2025)

Net assets of Centro de Imagem Diagnósticos S.A from 2010 to 2025. This chart illustrates how Centro de Imagem Diagnósticos S.A's net assets have evolved over time, based on quarterly financial data. See net asset quality index of Centro de Imagem Diagnósticos S.A to measure how much of total assets are equity-financed.

Annual Net Assets for Centro de Imagem Diagnósticos S.A (2010–2025)

The table below shows the annual net assets of Centro de Imagem Diagnósticos S.A from 2010 to 2025. For live market cap and overall valuation, see AALR3 market cap.

Year Net Assets Change
2025-12-31 R$-252.23 Million
≈ $-49.49 Million
-122.19%
2024-12-31 R$1.14 Billion
≈ $223.06 Million
+20.43%
2023-12-31 R$943.99 Million
≈ $185.23 Million
-3.86%
2022-12-31 R$981.92 Million
≈ $192.67 Million
-18.81%
2021-12-31 R$1.21 Billion
≈ $237.31 Million
-1.16%
2020-12-31 R$1.22 Billion
≈ $240.11 Million
-7.30%
2019-12-31 R$1.32 Billion
≈ $259.01 Million
+1.56%
2018-12-31 R$1.30 Billion
≈ $255.03 Million
+2.32%
2017-12-31 R$1.27 Billion
≈ $249.25 Million
+4.81%
2016-12-31 R$1.21 Billion
≈ $237.80 Million
+65.34%
2015-12-31 R$733.00 Million
≈ $143.83 Million
-1.39%
2014-12-31 R$743.32 Million
≈ $145.85 Million
+165.96%
2013-12-31 R$279.49 Million
≈ $54.84 Million
+18.97%
2012-12-31 R$234.93 Million
≈ $46.10 Million
-8.64%
2011-12-31 R$257.14 Million
≈ $50.46 Million
+621.00%
2010-12-31 R$35.66 Million
≈ $7.00 Million
--

Equity Component Analysis

This analysis shows how different components contribute to Centro de Imagem Diagnósticos S.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 200731800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Centro de Imagem Diagnósticos S.A Net Assets Breakdown (December 2025)

Centro de Imagem Diagnósticos S.A net assets breakdown by equity component as of December 2025.

Component Amount Percentage
Common Stock R$1.12 Billion %
Other Comprehensive Income R$608.25 Million %
Total Equity R$-277.54 Million 100.00%

Centro de Imagem Diagnósticos S.A Competitors by Market Cap

The table below lists competitors of Centro de Imagem Diagnósticos S.A ranked by their market capitalization.

Company Market Cap
Evergreen Corp
NASDAQ:EVGR
$64.59 Million
Seplat Petroleum Development Company PLC
LSE:SEPL
$64.60 Million
Quest For Growth - Pricaf
BR:QFG
$64.61 Million
Ariadne Australia Ltd
AU:ARA
$64.62 Million
Ascot Resources Ltd.
TO:AOT
$64.55 Million
LIG-ES SPAC
KQ:220260
$64.52 Million
Games Workshop Group PLC
LSE:GAW
$64.51 Million
Taiwan Allied Container Terminal
TWO:5601
$64.51 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Centro de Imagem Diagnósticos S.A's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 1,094,793,000 to -277,542,000, a change of -1,372,335,000 (-125.4%).
  • Net loss of 1,372,344,000 reduced equity.
  • Dividend payments of 17,227,000 reduced retained earnings.
  • New share issuances of 9,000 increased equity.
  • Other comprehensive income decreased equity by 511,000,000.
  • Other factors increased equity by 528,227,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income R$-1.37 Billion -494.46%
Dividends Paid R$17.23 Million -6.21%
Share Issuances R$9.00K +0.0%
Other Comprehensive Income R$-511.00 Million -184.12%
Other Changes R$528.23 Million +190.32%
Total Change R$- -125.35%

Book Value vs Market Value Analysis

This analysis compares Centro de Imagem Diagnósticos S.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2012-12-31 R$4.78 R$2.16 x
2013-12-31 R$5.43 R$2.16 x
2014-12-31 R$13.02 R$2.16 x
2015-12-31 R$7.79 R$2.16 x
2016-12-31 R$11.60 R$2.16 x
2017-12-31 R$10.41 R$2.16 x
2018-12-31 R$10.60 R$2.16 x
2019-12-31 R$10.87 R$2.16 x
2020-12-31 R$10.09 R$2.16 x
2021-12-31 R$10.00 R$2.16 x
2022-12-31 R$8.06 R$2.16 x
2023-12-31 R$7.76 R$2.16 x
2024-12-31 R$9.21 R$2.16 x
2025-12-31 R$-1.82 R$2.16 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Centro de Imagem Diagnósticos S.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 0.00%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -118.94%
  • • Asset Turnover: 0.65x
  • • Equity Multiplier: 0.00x
  • Recent ROE (0.00%) is above the historical average (-2.93%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2012 12.27% 15.48% 0.56x 1.41x R$5.28 Million
2013 10.15% 10.03% 0.47x 2.16x R$410.90K
2014 -0.57% -1.06% 0.27x 1.99x R$-77.74 Million
2015 -1.78% -1.82% 0.46x 2.15x R$-84.37 Million
2016 1.26% 1.55% 0.44x 1.85x R$-102.57 Million
2017 0.55% 0.62% 0.47x 1.87x R$-115.29 Million
2018 3.19% 3.72% 0.49x 1.76x R$-85.61 Million
2019 3.22% 3.85% 0.45x 1.87x R$-86.92 Million
2020 -8.18% -10.49% 0.37x 2.13x R$-216.47 Million
2021 -0.48% -0.49% 0.45x 2.16x R$-123.15 Million
2022 -23.99% -21.00% 0.41x 2.75x R$-322.78 Million
2023 -24.84% -19.32% 0.44x 2.91x R$-319.62 Million
2024 -11.79% -10.61% 0.42x 2.64x R$-238.60 Million
2025 0.00% -118.94% 0.65x 0.00x R$-1.34 Billion

Industry Comparison

This section compares Centro de Imagem Diagnósticos S.A's net assets metrics with peer companies in the Diagnostics & Research industry.

Industry Context

  • Industry: Diagnostics & Research
  • Average net assets among peers: $1,712,929,000
  • Average return on equity (ROE) among peers: 17.14%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Centro de Imagem Diagnósticos S.A (AALR3) R$-252.23 Million 12.27% N/A $64.56 Million
Diagnósticos da América S.A (DASA3) $3.32 Billion 3.96% 0.88x $799.44 Million
Fleury S.A. (FLRY3) $105.91 Million 30.32% 2.08x $2.14 Billion

About Centro de Imagem Diagnósticos S.A

SA:AALR3 Brazil Diagnostics & Research
Market Cap
$64.56 Million
R$329.02 Million BRL
Market Cap Rank
#20657 Global
#194 in Brazil
Share Price
R$2.16
Change (1 day)
-1.82%
52-Week Range
R$2.16 - R$5.40
All Time High
R$24.30
About

Alliança Saúde e Participações S.A. provides diagnostic imaging and medicine services in Brazil. The company offers diagnostic imaging, clinical analysis, nuclear medicine, genetic testing, and vaccination services, as well as corporate, remote, and in-person solutions for hospitals and diagnostic centers in the private and public sectors. It provides clinical analysis services, such as blood cou… Read more